The Paris-headquartered company said it expected 2023 adjusted earnings per share to grow by a "low single digit" percentage, not taking into account an expected negative currency impact of between 3.5% and 4.5%.
It also reported a 20.7% rise in fourth-quarter business operating income, or adjusted earnings before interest and tax, to 2.72 billion euros ($2.96 billion), edging past an average analyst estimate of 2.69 billion euros posted on the company's website. Revenue from eczema and asthma drug Dupixent, jointly developed with Regeneron , surged 42% to 2.4 billion euros during the quarter ended Dec. 31, slightly above a consensus of 2.37 billion euros.
The company said its ambition was to reach Dupixent sales of
10 billion euros this year, up more than 20% from 8.29 billion
euros in 2022.
($1 = 0.9180 euros)
(Reporting by Ludwig Burger; Editing by Rashmi Aich)
